[go: up one dir, main page]

WO2000006140A3 - Procedes et compositions permettant de traiter et de prevenir certains troubles psychiatriques et medicaux par le moclobemide - Google Patents

Procedes et compositions permettant de traiter et de prevenir certains troubles psychiatriques et medicaux par le moclobemide Download PDF

Info

Publication number
WO2000006140A3
WO2000006140A3 PCT/US1999/017417 US9917417W WO0006140A3 WO 2000006140 A3 WO2000006140 A3 WO 2000006140A3 US 9917417 W US9917417 W US 9917417W WO 0006140 A3 WO0006140 A3 WO 0006140A3
Authority
WO
WIPO (PCT)
Prior art keywords
moclobemide
phsychiatric
depression
treating
medical disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/017417
Other languages
English (en)
Other versions
WO2000006140A2 (fr
Inventor
Donald F Klein
Seth Lederman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tinea Pharmaceuticals Inc
Original Assignee
Janus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janus Pharmaceuticals Inc filed Critical Janus Pharmaceuticals Inc
Priority to MXPA01001178A priority Critical patent/MXPA01001178A/es
Priority to CA002338330A priority patent/CA2338330A1/fr
Priority to JP2000561995A priority patent/JP2002521433A/ja
Priority to AU53305/99A priority patent/AU5330599A/en
Publication of WO2000006140A2 publication Critical patent/WO2000006140A2/fr
Publication of WO2000006140A3 publication Critical patent/WO2000006140A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des procédés et des compositions dans lesquels on utilise le moclobémide, un métabolite du moclobémide, un dérivé du moclobémide ou une composition de moclobémide pour faciliter le traitement ou la prévention des troubles affectifs avec apathie, de la dépression des adolescents, de la dépression partielle rebelle à la thérapie, de la dépression atypique partielle rebelle à la thérapie, des problèmes d'alimentation et des symptômes de ces troubles. L'invention permet également de traiter les symptômes de somatisation, les troubles de l'apprentissage et du comportement par le moclobémide, un métabolite du moclobémide, un dérivé du moclobémide ou une composition de moclobémide.
PCT/US1999/017417 1998-07-31 1999-07-30 Procedes et compositions permettant de traiter et de prevenir certains troubles psychiatriques et medicaux par le moclobemide Ceased WO2000006140A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MXPA01001178A MXPA01001178A (es) 1998-07-31 1999-07-30 Metodos y composiciones para tratamiento y la prevencion de ciertos trastornos psiquiatricos y medicos mediante el empleo de la moclobemida.
CA002338330A CA2338330A1 (fr) 1998-07-31 1999-07-30 Procedes et compositions permettant de traiter et de prevenir certains troubles psychiatriques et medicaux par le moclobemide
JP2000561995A JP2002521433A (ja) 1998-07-31 1999-07-30 モクロベマイドを用いる、ある種の精神医学的および医学的異常の処置と予防の方法および組成物
AU53305/99A AU5330599A (en) 1998-07-31 1999-07-30 Methods and compositions for treating and preventing certain psychiatric and medical disorders using moclobemide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9498598P 1998-07-31 1998-07-31
US60/094,985 1998-07-31

Publications (2)

Publication Number Publication Date
WO2000006140A2 WO2000006140A2 (fr) 2000-02-10
WO2000006140A3 true WO2000006140A3 (fr) 2000-05-18

Family

ID=22248342

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/017417 Ceased WO2000006140A2 (fr) 1998-07-31 1999-07-30 Procedes et compositions permettant de traiter et de prevenir certains troubles psychiatriques et medicaux par le moclobemide

Country Status (5)

Country Link
JP (1) JP2002521433A (fr)
AU (1) AU5330599A (fr)
CA (1) CA2338330A1 (fr)
MX (1) MXPA01001178A (fr)
WO (1) WO2000006140A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1078632A1 (fr) * 1999-08-16 2001-02-28 Sanofi-Synthelabo Utilisation des inhibiteurs de monoamine oxydases dans la fabrication d'un médicament contre l'obésité
WO2005053703A1 (fr) 2003-12-02 2005-06-16 Leslie James Sheldon Polytherapie contre la demence, la depression et l'apathie
EP4633638A1 (fr) * 2022-12-14 2025-10-22 Luminous Mind Inc. Traitement de facteurs psychologiques affectant d'autres problèmes de santé (pfaomc)

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
COQUOZ D ET AL: "Central analgesic effects of desipramine, fluvoxamine, and moclobemide after single oral dosing: a study in healthy volunteers.", CLINICAL PHARMACOLOGY AND THERAPEUTICS, (1993 SEP) 54 (3) 339-44., XP000884639 *
ELMORE J.L. ET AL: "Female sexual stimulation during antidepressant treatment.", PHARMACOTHERAPY, (1997) 17/3 (612-616)., XP000884562 *
FITTON A. ET AL: "Moclobemide: A review of its pharmacological properties and therapeutic use in depressive illness.", DRUGS, (1992) 43/4 (561-596)., XP000884801 *
HAZELL P.: "Stimulant treatment for attention deficit hyperactivity disorder.", AUSTRALIAN PRESCRIBER, (1995) 18/3 (60-64)., XP000884703 *
KRAUSE K.-H. ET AL: "[Pilot study on the efficacy of moclobemide on pain in fibromyalgia syndrome]. WIRKUNG VON MOCLOBEMID AUF SCHMERZEN BEI FIBROMYALGIE. ERGEBNISSE EINER PILOTSTUDIE.", PSYCHOPHARMAKOTHERAPIE, (1998) 5/1 (29-30)., XP000884815 *
LIEBOWITZ M R ET AL: "Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders.", ACTA PSYCHIATRICA SCANDINAVICA. SUPPLEMENTUM, (1990) 360 29-34. REF: 43, XP000650509 *
LINGJAERDE O. ET AL: "Treatment of winter depression in Norway. II. A comparison of the selective monoamine oxidase A inhibitor moclobemide and placebo.", ACTA PSYCHIATRICA SCANDINAVICA, (1993) 88/5 (372-380)., XP000884817 *
MENKES D B ET AL: "Moclobemide in chronic neuropathic pain: preliminary case reports.", CLINICAL JOURNAL OF PAIN, (1995 JUN) 11 (2) 134-8., XP000884630 *
PRIEST R.G. ET AL: "Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders.", ACTA PSYCHIATRICA SCANDINAVICA, SUPPLEMENT, (1995) 91/386 (40-43)., XP000884763 *
SAEED S.A. ET AL: "Seasonal affective disorders.", AMERICAN FAMILY PHYSICIAN, (15 MAR 1998) 57/6 (1340-1346)., XP000884764 *
WHITE P.D. ET AL: "An open study of the efficacy and adverse effects of moclobemide in patients with the chronic fatigue syndrome.", INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, (1997) 12/1 (47-52)., XP000884709 *

Also Published As

Publication number Publication date
CA2338330A1 (fr) 2000-02-10
WO2000006140A2 (fr) 2000-02-10
JP2002521433A (ja) 2002-07-16
AU5330599A (en) 2000-02-21
MXPA01001178A (es) 2002-04-24

Similar Documents

Publication Publication Date Title
WO2001062290A3 (fr) Methodes et compositions destinees a ameliorer la qualite du sommeil
WO2002040544A3 (fr) Facteur ix humain mutant a resistance accrue a l'inhibition par l'heparine
EP1808177A3 (fr) Procédés de traitement des troubles mitochondriaux
PT1446387E (pt) Derivados de aril-1,4-pirazina substituídos
MY130489A (en) Substituted aryl 1, 4-pyrazine derivatives
AU2002361811A1 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
WO2002009699A3 (fr) Procede pour traiter les symptomes du rhume, la rhinite allergique et les infections liees aux voies respiratoires
WO2004019884A3 (fr) Agents et procedes pour stimuler la formation osseuse
KR960706589A (ko) 티슈 페이퍼에 연성 및 윤활성 감촉을 부여하기 위한 로션 조성물(lotion composition for imparting soft, lubricious feel to tissue paper)
DK1331927T3 (da) Topisk komposition der indeholder mindst et D-vitamin eller en D-vitamin analog og mindst et kosttikosteroid
WO1995017165A3 (fr) Compositions anti-microbiennes d'humidification des tissus
WO2001079169A3 (fr) Antagonistes du recepteur de prostaglandine d2
WO2000015201A3 (fr) COMPOSITIONS COMPRENANT UN OU PLUSIEURS PHYTOSTEROLS, PHYTOSTANOLS, OU LEURS MELANGES, UN OU PLUSIEURS TOCOTRIENOLS, $G(ab, $G(b), $G(d) OU $G(g), OU LEURS DERIVES, UTILISATION DE CES COMPOSITIONS POUR TRAITER OU PREVENIR L'AFFECTION CARDIO-VASCULAIRE, SES ATTEINTES SOUS-JACENTES ET D'AUTRES ETATS PATHOLOGIQUES
BR0014312A (pt) Combinação de loteprednol e anti-histaminas
AU2386201A (en) Substituted sapogenins and their use
TW200509937A (en) Novel compounds and their use in therapy
WO2005016455A3 (fr) Anticorps variables
EE200000050A (et) Ravimkoostised, kasutusvalmis komplektid ja meetodid peaaju neurovaskulaarsete häirete ja lihaspingepeavalu inhibeerimiseks
AU2002220803A1 (en) Composition, in particular cosmetic, containing 7-hydroxy dhea and/or 7-keto dhea and at least an isoflavonoid
CA2474511A1 (fr) Derives de benzofurane et de benzothiophene utilises dans le traitement de troubles hyperproliferatifs
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
WO2003039453A3 (fr) Compositions de peroxyde de dibenzoyle pour le traitement de troubles dermatologiques, et procedes d'utilisation correspondants
DE60025639D1 (de) Substituierte diazepan
AU2001242130A1 (en) Novel derivatives comprising phytosterols and/or phytostanols and alpha-lipoic and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2338330

Country of ref document: CA

Ref country code: CA

Ref document number: 2338330

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09772675

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/001178

Country of ref document: MX

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase